Literature DB >> 21290160

Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.

Maria Pia Giannoccaro, Vincenzo Donadio, Carolina Gomis Pèrez, Walter Borsini, Vitantonio Di Stasi, Rocco Liguori.   

Abstract

Bortezomib is a new chemotherapeutic agent approved for the treatment of relapsed/refractory and newly diagnosed multiple myeloma. One of the major side effects of bortezomib is a peripheral length-dependent sensory axonal neuropathy and, less frequently, a small fiber neuropathy. Autonomic symptoms like postural dizziness, syncope, diarrhoea, ileus, impotence and urinary disturbances have been reported, nevertheless, autonomic neuropathy has never been characterized. We describe by means of immunofluorescence, the involvement of autonomic skin nerve fibers in three patients with small fiber neuropathy induced by bortezomib treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21290160     DOI: 10.1007/s10072-010-0475-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Life-threatening motor neurotoxicity in association with bortezomib.

Authors:  Sunil Gupta; Antonio Pagliuca; Steve Devereux; Ghulam J Mufti; Steve Schey
Journal:  Haematologica       Date:  2006-06-01       Impact factor: 9.941

2.  Quantitative sensory findings in patients with bortezomib-induced pain.

Authors:  Juan P Cata; Han-Rong Weng; Allen W Burton; Horatio Villareal; Sergio Giralt; Patrick M Dougherty
Journal:  J Pain       Date:  2006-12-15       Impact factor: 5.820

3.  Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

Authors:  Guido Cavaletti; Alessandra Gilardini; Annalisa Canta; Laura Rigamonti; Virginia Rodriguez-Menendez; Cecilia Ceresa; Paola Marmiroli; Mario Bossi; Norberto Oggioni; Maurizio D'Incalci; Roland De Coster
Journal:  Exp Neurol       Date:  2007-01-09       Impact factor: 5.330

4.  Autonomic innervation in multiple system atrophy and pure autonomic failure.

Authors:  V Donadio; P Cortelli; M Elam; V Di Stasi; P Montagna; B Holmberg; M P Giannoccaro; E Bugiardini; P Avoni; A Baruzzi; R Liguori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-26       Impact factor: 10.154

5.  Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.

Authors:  Cristina Meregalli; Annalisa Canta; Valentina A Carozzi; Alessia Chiorazzi; Norberto Oggioni; Alessandra Gilardini; Cecilia Ceresa; Federica Avezza; Luca Crippa; Paola Marmiroli; Guido Cavaletti
Journal:  Eur J Pain       Date:  2009-08-19       Impact factor: 3.931

Review 6.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Authors:  Andreas A Argyriou; Gregoris Iconomou; Haralabos P Kalofonos
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

Review 7.  Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy.

Authors:  J P Cata; H R Weng; B N Lee; J M Reuben; P M Dougherty
Journal:  Minerva Anestesiol       Date:  2006-03       Impact factor: 3.051

8.  Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.

Authors:  Vittorio Perfetti; Giovanni Palladini; Laura Brunetti; Adele Sgarella; Silvia Brugnatelli; Paolo G Gobbi; Gino Roberto Corazza
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-07       Impact factor: 2.566

9.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Authors:  Paul G Richardson; Wanling Xie; Constantine Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David E Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh Kesari; Hannah R Briemberg; Robert L Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie-Lee Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544

10.  Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.

Authors:  Antonia Field-Smith; Gareth J Morgan; Faith E Davies
Journal:  Ther Clin Risk Manag       Date:  2006-09       Impact factor: 2.423

  10 in total
  16 in total

Review 1.  Small-fibre neuropathies--advances in diagnosis, pathophysiology and management.

Authors:  Janneke G Hoeijmakers; Catharina G Faber; Giuseppe Lauria; Ingemar S Merkies; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2012-05-29       Impact factor: 42.937

2.  Bortezomib-induced severe autonomic neuropathy.

Authors:  A Stratogianni; M Tosch; H Schlemmer; J Weis; I Katona; S Isenmann; C A Haensch
Journal:  Clin Auton Res       Date:  2012-04-25       Impact factor: 4.435

3.  Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.

Authors:  Ilja Bobylev; Dominik Peters; Maulik Vyas; Mohammed Barham; Ines Klein; Elke Pogge von Strandmann; Wolfram F Neiss; Helmar C Lehmann
Journal:  Neurotox Res       Date:  2017-06-13       Impact factor: 3.911

4.  Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.

Authors:  Matthew Keating; Constantin A Dasanu
Journal:  BMJ Case Rep       Date:  2016-11-29

Review 5.  Cardiovascular Autonomic Dysfunction in Patients with Cancer.

Authors:  Ben G T Coumbe; John D Groarke
Journal:  Curr Cardiol Rep       Date:  2018-07-03       Impact factor: 2.931

Review 6.  Uses of skin biopsy for sensory and autonomic nerve assessment.

Authors:  M Iliza Myers; Amanda C Peltier
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 7.  Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Yaqin Han; Maree T Smith
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

8.  Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.

Authors:  Jarmila Lakomá; Roberto Rimondini; Vincenzo Donadio; Rocco Liguori; Marco Caprini
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

9.  Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.

Authors:  Valentina A Carozzi; Cynthia L Renn; Michela Bardini; Grazia Fazio; Alessia Chiorazzi; Cristina Meregalli; Norberto Oggioni; Kathleen Shanks; Marina Quartu; Maria Pina Serra; Barbara Sala; Guido Cavaletti; Susan G Dorsey
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

10.  A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.

Authors:  Takashi Watanabe; Kensei Tobinai; Morio Matsumoto; Kenshi Suzuki; Kazutaka Sunami; Tadao Ishida; Kiyoshi Ando; Takaaki Chou; Shuji Ozaki; Masafumi Taniwaki; Naokuni Uike; Hirohiko Shibayama; Kiyohiko Hatake; Koji Izutsu; Takayuki Ishikawa; Yoshihisa Shumiya; Tomohisa Kashihara; Shinsuke Iida
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.